Production (Stage)
Kezar Life Sciences, Inc.
KZR
$4.40
$0.020.46%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -- | -- |
| Cost of Revenue | -27.92% | -43.32% | -29.18% | -7.88% | 43.25% |
| Gross Profit | 19.56% | 38.28% | 22.18% | 18.16% | -28.36% |
| SG&A Expenses | -17.01% | -11.86% | -9.04% | 20.05% | 25.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.46% | -20.58% | -7.61% | 18.03% | 39.62% |
| Operating Income | 20.47% | 15.30% | 0.94% | -10.27% | -30.84% |
| Income Before Tax | 22.40% | 17.80% | -9.10% | -19.43% | -36.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 22.40% | 17.80% | -9.10% | -19.43% | -36.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.40% | 17.80% | -9.10% | -19.43% | -36.17% |
| EBIT | 20.47% | 15.30% | 0.94% | -10.27% | -30.84% |
| EBITDA | 20.64% | 15.43% | 0.97% | -10.57% | -31.83% |
| EPS Basic | 2.84% | -1.56% | -8.52% | -18.68% | -31.82% |
| Normalized Basic EPS | -1.94% | -6.59% | 0.18% | -9.45% | -23.78% |
| EPS Diluted | 2.84% | -1.56% | -8.52% | -18.68% | -31.82% |
| Normalized Diluted EPS | -1.94% | -6.59% | 0.18% | -9.45% | -23.78% |
| Average Basic Shares Outstanding | 0.41% | 0.48% | 0.57% | 0.65% | 3.45% |
| Average Diluted Shares Outstanding | 0.41% | 0.48% | 0.57% | 0.65% | 3.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |